Cite

HARVARD Citation

    Uldrick, T. et al. (2017). A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma. Oncologist. pp. 505-e49. [Online]. 
  
Back to record